RIG2.F Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
- Market cap
- EUR 6.84B
- P/E
- 12.1x
- P/B
- 1.73x
- ROE
- 16.6%
- Dividend yield
- 5.09%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is RIG2.F undervalued?
Graham numberRIG2.F trades 3.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt fundamental analysis
No fundamental analysis for Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt yet.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-a…
Full company profileRichter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt financial statements
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt annual financial statements (HUF; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 390B | 444B | 445B | 508B | 567B | 631B | 803B | 805B | 858B | 929B |
| Gross Profit | 226B | 253B | 254B | 283B | 319B | 349B | 460B | 521B | 591B | 641B |
| Operating Income | 54.6B | 20.7B | 44.6B | 83.6B | 131B | 136B | 152B | 246B | 270B | 327B |
| EBITDA | - | 49.6B | 78.9B | 90.8B | 156B | 192B | 222B | 238B | 346B | 356B |
| Net Income | 66.2B | 8.89B | 35.3B | 47.1B | 105B | 140B | 156B | 159B | 239B | 232B |
| EPS | - | 48 | 190 | 254 | 564 | 751 | 837 | 869 | 1,312 | 1,274 |
| Balance Sheet | ||||||||||
| Total Assets | 814B | 761B | 798B | 859B | 949B | 1.15T | 1.34T | 1.36T | 1.61T | 1.70T |
| Total Liabilities | 132B | 96.8B | 112B | 134B | 135B | 222B | 280B | 219B | 303B | 297B |
| Shareholders' Equity | 678B | 659B | 680B | 718B | 807B | 915B | 1.05T | 1.13T | 1.30T | 1.40T |
| Cash & Short-term Investments | 96.1B | 76.0B | 113B | 129B | 142B | 59.9B | 79.7B | 80.5B | 136B | 212B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 77.4B | 83.7B | 100B | 98.2B | 134B | 140B | 185B | 146B | 279B | 276B |
| Capital Expenditure | 36.5B | 30.3B | 42.0B | 39.5B | 36.9B | 46.1B | 59.2B | 95.6B | 63.7B | 66.4B |
| Free Cash Flow | - | 43.8B | 43.2B | 40.1B | 66.9B | -3.39B | 113B | 50.2B | 216B | 210B |
| Ratios | ||||||||||
| ROE | 9.8% | 1.3% | 5.2% | 6.6% | 13.0% | 15.3% | 14.8% | 14.0% | 18.4% | 16.6% |
| ROA | 8.1% | 1.2% | 4.4% | 5.5% | 11.0% | 12.2% | 11.6% | 11.7% | 14.9% | 13.7% |
| Net Profit Margin | 17.0% | 2.0% | 7.9% | 9.3% | 18.5% | 22.1% | 19.4% | 19.7% | 27.9% | 25.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt dividends
- Dividend yield
- 5.09%
- Forward dividend
- 1.83 EUR
- Payout ratio
- 40.1%
- Ex-dividend date
- Jun 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | HUF 93.1B | 510 | 40.1% |
| 2024 | HUF 79.1B | 434 | 33.1% |
| 2023 | HUF 73.0B | 400 | 46.0% |
| 2022 | HUF 41.9B | 226 | 27.0% |
| 2021 | HUF 41.9B | 226 | 30.0% |
| 2020 | HUF 11.7B | 63 | 11.2% |
| 2019 | EUR 18.6B | 100 | 39.5% |
| 2018 | EUR 12.7B | 68 | 35.9% |
| 2017 | EUR 19.8B | 106 | 222.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10:1 on Jul 11, 2013.
Who owns Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
- Insiders 25.25%
- Institutions 39.41%
- Public & others 35.34%
- Shares outstanding 182M
- Free float 183M
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt company profile
- Company name
- Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
- Ticker
- RIG2.F
- ISIN
- HU0000123096
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 11,155
- Fiscal year end
- December
- Address
- Gyömroi út 19-21, Budapest, Hungary, 1103
- Phone
- 36 1 431 4000
- Website
- gedeonrichter.com
About Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
Gedeon Richter PLC researches, develops, manufactures, markets, and sells pharmaceutical products. It offers women's healthcare products for contraceptives, endometriosis, fertility, menopause, vaginal infections, and uterine fibroids; and Femtech, a digital therapeutic solution to enhance women's lives. It also provides central nervous system products, such as products for the treatment of chronic cerebral circulatory disorders and neuropathic pain; and anaesthetics, anti-anxiety medications, sleeping pills, and anti-epileptic medicines, as well as products for the prevention and treatment of various cardiovascular diseases. In addition, it produces various over-the-counter products for various health problems comprising Panangin for heart support; Escapelle and Postinor, which are emergency contraceptive pills; Stopdiar and Nifuroxazide to treat diarrhea; RICHTER CycleBalance for infertility and PCOS; Curiosin for wound healing; Groprinosin for antiviral and immunostimulant; Folik, a pregnancy supplement; Moilec for back and joint pain; Fasconal, a pain relief tablet; Lordestin for allergies; Magnezin, a magnesium supplement; Aflamil, an anti-inflammatory and antirheumatic cream; and Oralsept, a sore throat and local anesthetic. Further, it engages in the provision of financial accounting, social and welfare, portfolio management, catering, carriage transportation, engineering, asset management, and biotechnological manufacturing and research services; pharmaceutical retail; trading of biotech products; and sale of medical equipment. It has strategic co-development and license agreement with Adalvo Ltd. for a proposed bioequivalent to Semaglutide injection, a GLP-1 receptor agonist indicated for chronic weight management. Additionally, it has a strategic research collaboration with FimmCyte AG for the development of first-in-class antibody, "FMC2', for the treatment of endometriosis. The company was founded in 1901 and is headquartered in Budapest, Hungary.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt management
5- Mr. Gabor OrbanCEO & Director · born 1979
- Mr. Laszlo Andras KovacsGroup Head of Controlling, CFO & Director
- Ms. Katalin ErdeiHuman Resources & Technical Director · born 1974
- Mr. Robert RethyHead of the Investor Relations & ESG Department
- Mr. Tamas SzolyakDirector of Global Regulatory Science, Commerce & Marketing · born 1966